Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Sends “Dear Doctor” Letter On Clozaril

This article was originally published in The Pink Sheet Daily

Executive Summary

Clarification of white blood cell monitoring schedule is key concern of the letter.

You may also be interested in...



Clozapine Reaction Shows Comparative Effectiveness In Transition

A recent study in The Lancet generated significant attention after showing much lower death rates for schizophrenia sufferers taking the cheap generic antipsychotic clozapine compared with branded drugs

Clozapine Reaction Shows Comparative Effectiveness In Transition

A recent study in The Lancet generated significant attention after showing much lower death rates for schizophrenia sufferers taking the cheap generic antipsychotic clozapine compared with branded drugs

Novartis Clozaril Blood Monitoring Requirements Relaxed By FDA

FDA agrees to labeling change decreasing monitoring requirements for agranulocytosis to once monthly from twice a month. The agency asks Novartis to track agranulocytosis rates in the national registry.

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel